Aardvark Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Selling, General & Admin	7.16	5.31	2.17	2.7
Research & Development	23.91	17.36	4.48	7.17
Operating Expenses	31.08	22.79	7.42	10.36
Operating Income	-31.08	-22.79	-7.42	-10.36
Interest & Investment Income	3.49	2.41	1.42	0.12
EBT Excluding Unusual Items	-27.6	-20.37	-5.99	-10.24
Gain (Loss) on Sale of Investments	-0.12	-0.22	-1.22	-2.32
Asset Writedown	-	-	-	-1
Pretax Income	-27.72	-20.59	-7.21	-13.56
Net Income	-27.72	-20.59	-7.21	-13.56
Net Income to Common	-27.72	-20.59	-7.21	-13.56
Shares Outstanding (Basic)	6	4	4	4
Shares Outstanding (Diluted)	6	4	4	4
Shares Change (YoY)	59.04%	0.90%	1.78%	-
EPS (Basic)	-4.40	-5.15	-1.82	-3.49
EPS (Diluted)	-4.40	-5.15	-1.82	-3.49
Free Cash Flow	-27.39	-18.2	-5.82	-10.54
Free Cash Flow Per Share	-4.34	-4.55	-1.47	-2.71
EBITDA	-31.07	-22.77	-	-
D&A For EBITDA	0.02	0.02	-	-
EBIT	-31.08	-22.79	-7.42	-10.36

Updated Mar 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q